Video

Breast Cancer Treatment Updates

Experts discuss the role of pharmacists in improving screening rates for breast cancer, how they can support patients, and improve outcomes.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
5 experts in this video
1 expert is featured in this series.
Magnified bone marrow biopsy showing plasma cells with irregular nuclei and multiple myeloma tumor cells infiltrating normal hematopoietic tissue
5 experts in this video
5 experts in this video
Image credit: Dr_Microbe | stock.adobe.com
1 expert is featured in this series.
Related Content
Doctor holding bladder model | Image Credit: © M+Isolation+Photo - stock.adobe.com
June 12th 2025

Mitomycin Intravesical Solution Receives FDA Approval for Non-Muscle Invasive Bladder Cancer

Alexandra Gerlach, Associate Editor
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
Oral herbal supplement -- Image credit: Vitalii Vodolazskyi | stock.adobe.com
June 12th 2025

You Shall Not Pass: Pharmacist Review of Drug-Herb Interactions in Cancer Treatment

Hanna Yakubi, PharmD Cody Angerman, PharmD Iris Zhao, PharmD, BCOP, BCPS, APh Saumya Papneja, PharmD, BCOP Christina Marengo, PharmD Mency Zhu, PharmD Ryan Beechinor, PharmD, BCPS, BCOP
Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings
May 28th 2025

Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings

Alexandra Gerlach, Associate Editor
FDA Approves Tablet Formulation of Zanubrutinib for All Indications
June 11th 2025

FDA Approves Tablet Formulation of Zanubrutinib for All Indications

Luke Halpern, Assistant Editor
Image credit: David A Litman | stock.adobe.com
June 11th 2025

Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC

Gillian McGovern, Associate Editor